

Daniel E Singer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/548248/publications.pdf>

Version: 2024-02-01

125
papers

24,751
citations

61857

43
h-index

18075

120
g-index

131
all docs

131
docs citations

131
times ranked

18329
citing authors

#	ARTICLE	IF	CITATIONS
1	Profile of Patients with Isolated Distal Deep Vein Thrombosis versus Proximal Deep Vein Thrombosis or Pulmonary Embolism: RE-COVERY DVT/PE Study. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 446-458.	1.5	15
2	Safety and effectiveness of dabigatran in routine clinical practice: the RE-COVERY DVT/PE study. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 399-409.	1.0	3
3	Screening for Atrial Fibrillation in Older Adults at Primary Care Visits: VITAL-AF Randomized Controlled Trial. <i>Circulation</i> , 2022, 145, 946-954.	1.6	43
4	Management of Adults with Newly Diagnosed Atrial Fibrillation with and without CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 442-453.	3.0	3
5	ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals (GUARD-AF): Rationale and Design of the GUARD-AF Randomized Trial of Screening for Atrial Fibrillation with a 14-day Patch-Based Continuous ECG Monitor. <i>American Heart Journal</i> , 2022, 249, 76-76.	1.2	3
6	Trends in Consumer Wearable Devices With Cardiac Sensors in a Primary Care Cohort. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2022, 15, .	0.9	13
7	Comparative Effectiveness of Postdischarge Smoking Cessation Interventions for Hospital Patients. <i>JAMA Internal Medicine</i> , 2022, 182, 814.	2.6	10
8	Patterns of oral anticoagulation use with cardioversion in clinical practice. <i>Heart</i> , 2021, 107, 642-649.	1.2	3
9	Automated Electronic Phenotyping of Cardioembolic Stroke. <i>Stroke</i> , 2021, 52, 181-189.	1.0	22
10	Profile of patients diagnosed with acute venous thromboembolism in routine practice according to age and renal function: RE-COVERY DVT/PE study. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 561-570.	1.0	0
11	Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II). <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 553-561.	1.0	5
12	Usefulness of Rhythm Monitoring Following Acute Ischemic Stroke. <i>American Journal of Cardiology</i> , 2021, 147, 44-51.	0.7	3
13	Cigarette Smoking and Risk Perceptions During the COVID-19 Pandemic Reported by Recently Hospitalized Participants in a Smoking Cessation Trial. <i>Journal of General Internal Medicine</i> , 2021, 36, 3786-3793.	1.3	42
14	Rationale and design of a large population study to validate software for the assessment of atrial fibrillation from data acquired by a consumer tracker or smartwatch: The Fitbit heart study. <i>American Heart Journal</i> , 2021, 238, 16-26.	1.2	61
15	Comparative Clinical Effectiveness of Population-Based Atrial Fibrillation Screening Using Contemporary Modalities: A Decision-Analytic Model. <i>Journal of the American Heart Association</i> , 2021, 10, e020330.	1.6	4
16	Temporal Association Between Episodes of Atrial Fibrillation and Risk of Ischemic Stroke. <i>JAMA Cardiology</i> , 2021, 6, 1364.	3.0	47
17	Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e022485.	1.6	0
18	Research Priorities in Atrial Fibrillation Screening. <i>Circulation</i> , 2021, 143, 372-388.	1.6	42

#	ARTICLE	IF	CITATIONS
19	Point-of-care screening for atrial fibrillation: Where are we, and where do we go next?. Cardiovascular Digital Health Journal, 2021, 2, 294-297.	0.5	1
20	Reâ€CHARGEâ€CAF: Recalibration of the CHARGEâ€CAF Model for Atrial Fibrillation Risk Prediction in Patients With Acute Stroke. Journal of the American Heart Association, 2021, 10, e022363.	1.6	8
21	Understanding engagement behaviors and rapport building in tobacco cessation telephone counseling: An analysis of audio-recorded counseling calls. Journal of Substance Abuse Treatment, 2021, , 108643.	1.5	2
22	Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. American Heart Journal, 2020, 220, 145-154.	1.2	3
23	Cost-Effectiveness of Extended and One-Time Screening Versus No Screening for Non-Valvular Atrial Fibrillation in the USA. Applied Health Economics and Health Policy, 2020, 18, 533-545.	1.0	11
24	Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillation. American Heart Journal, 2020, 223, 65-71.	1.2	22
25	Risk of Ischemic Stroke and Major Bleeding in Patients with Atrial Fibrillation and Cancer. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 104560.	0.7	20
26	Comparison of Long-Term Adverse Outcomes in Patients With Atrial Fibrillation Having Ablation Versus Antiarrhythmic Medications. American Journal of Cardiology, 2020, 125, 553-561.	0.7	5
27	Effect of Temporary Interruption of Warfarin Due to an Intervention on Downstream Time in Therapeutic Range in Patients With Atrial Fibrillation (from ORBIT AF). American Journal of Cardiology, 2020, 132, 66-71.	0.7	1
28	Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice. Circulation: Cardiovascular Interventions, 2020, 13, e008274.	1.4	1
29	Shared decision-making in atrial fibrillation: patient-reported involvement in treatment decisions. European Heart Journal Quality of Care & Clinical Outcomes, 2020, 6, 263-272.	1.8	16
30	Initial Precipitants and Recurrence of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e007716.	2.1	37
31	Comparative effectiveness of post-discharge strategies for hospitalized smokers: Study protocol for the Helping HAND 4 randomized controlled trial. Trials, 2020, 21, 336.	0.7	10
32	Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PEâ„¢ Study. American Journal of Medicine, 2020, 133, 936-945.	0.6	10
33	Reversal strategies and outcomes in patients with atrial fibrillation and warfarin-associated intracranial hemorrhage. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 104903.	0.7	0
34	Incremental prognostic value of renal function for stroke prediction in atrial fibrillation. International Journal of Cardiology, 2019, 274, 152-157.	0.8	7
35	Design and rationale of a pragmatic trial integrating routine screening for atrial fibrillation at primary care visits: The VITAL-AF trial. American Heart Journal, 2019, 215, 147-156.	1.2	24
36	Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. JAMA Cardiology, 2019, 4, 756.	3.0	10

#	ARTICLE	IF	CITATIONS
37	Ischemic and Thrombotic Events Associated with Concomitant Xa-inhibiting Direct Oral Anticoagulants and Antiepileptic Drugs: Analysis of the FDA Adverse Event Reporting System (FAERS). <i>CNS Drugs</i> , 2019, 33, 1223-1228.	2.7	22
38	Defining Clinically Important Difference in the Atrial Fibrillation Effect on Quality-of-Life Score. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005358.	0.9	59
39	Perioperative/Postoperative Atrial Fibrillation and Risk of Subsequent Stroke and/or Mortality. <i>Stroke</i> , 2019, 50, 1364-1371.	1.0	147
40	Disparities in Quality of Primary Care by Resident and Staff Physicians: Is There a Conflict Between Training and Equity?. <i>Journal of General Internal Medicine</i> , 2019, 34, 1184-1191.	1.3	22
41	Risk factors for medication non-adherence among atrial fibrillation patients. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 38.	0.7	36
42	Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e007612.	2.1	27
43	Unrecognized History of Transient Atrial Fibrillation at the Time of Discharge from an Index Stroke Hospitalization Is Associated with Increased Recurrent Stroke Risk. <i>Journal of Stroke</i> , 2019, 21, 190-194.	1.4	2
44	Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF. <i>International Journal of Cardiology</i> , 2018, 257, 78-83.	0.8	10
45	Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation. <i>Circulation</i> , 2018, 138, 889-897.	1.6	23
46	Anxiety, Depression, and Adverse Clinical Outcomes in Patients With Atrial Fibrillation Starting Warfarin: Cardiovascular Research Network WAVE Study. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	29
47	Improvements in health-related quality of life among smokers who quit after hospitalization. <i>Preventive Medicine</i> , 2018, 110, 38-46.	1.6	9
48	Identifying Patients With High Data Completeness to Improve Validity of Comparative Effectiveness Research in Electronic Health Records Data. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 899-905.	2.3	40
49	Association of of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes. <i>JAMA Cardiology</i> , 2018, 3, 54.	3.0	77
50	Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2018, 3, 1174.	3.0	111
51	Electronic physician notifications to improve guideline-based anticoagulation in atrial fibrillation: a randomized controlled trial. <i>Journal of General Internal Medicine</i> , 2018, 33, 2070-2077.	1.3	24
52	Association of Intracranial Hemorrhage Risk With Non-Vitamin K Antagonist Oral Anticoagulant Use vs Aspirin Use. <i>JAMA Neurology</i> , 2018, 75, 1511.	4.5	24
53	Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation. <i>Heart</i> , 2018, 104, 1850-1858.	1.2	23
54	Methodologic Differences Across Studies of Patients With Atrial Fibrillation Lead to Varying Estimates of Stroke Risk. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	5

#	ARTICLE	IF	CITATIONS
55	Smoking Cessation After Hospital Discharge: Factors Associated With Abstinence. <i>Journal of Hospital Medicine</i> , 2018, 13, 774-778.	0.7	10
56	First Diagnosis of Atrial Fibrillation at the Time of Stroke. <i>Cerebrovascular Diseases</i> , 2017, 43, 192-199.	0.8	43
57	Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin. <i>Circulation</i> , 2017, 135, 1001-1003.	1.6	30
58	Health Literacy and Awareness of Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	52
59	Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	0.9	8
60	Ischemic Stroke in Nonvalvular Atrial Fibrillation at Warfarin Initiation. <i>Stroke</i> , 2017, 48, 1487-1494.	1.0	8
61	Changes in Use of Anticoagulation in Patients With Atrial Fibrillation Within a Primary Care Network Associated With the Introduction of Direct Oral Anticoagulants. <i>American Journal of Cardiology</i> , 2017, 120, 786-791.	0.7	30
62	Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	8
63	Interactive Voice Response Calls to Promote Smoking Cessation after Hospital Discharge: Pooled Analysis of Two Randomized Clinical Trials. <i>Journal of General Internal Medicine</i> , 2017, 32, 1005-1013.	1.3	20
64	Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial). <i>American Journal of Cardiology</i> , 2017, 120, 588-594.	0.7	36
65	Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.7	74
66	Use of Oral Anticoagulant Therapy in Older Adults with Atrial Fibrillation After Acute Ischemic Stroke. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 241-248.	1.3	48
67	Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1325-1335.	1.2	124
68	Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	106
69	Examining the effects of illicit drug use on tobacco cessation outcomes in the Helping HAND 2 randomized controlled trial. <i>Drug and Alcohol Dependence</i> , 2017, 178, 586-592.	1.6	6
70	Wide Variation in Reported Rates of Stroke Across Cohorts of Patients With Atrial Fibrillation. <i>Circulation</i> , 2017, 135, 208-219.	1.6	103
71	Influence of Competing Risks on Estimating the Expected Benefit of Warfarin in Individuals with Atrial Fibrillation Not Currently Taking Anticoagulants: The Anticoagulation and Risk Factors in Atrial Fibrillation Study. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 35-41.	1.3	13
72	NOACs for treatment of venous thromboembolism in clinical practice. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1317-1325.	1.8	18

#	ARTICLE	IF	CITATIONS
73	Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice. <i>Annals of Internal Medicine</i> , 2017, 167, 845.	2.0	37
74	RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate. <i>Thrombosis and Haemostasis</i> , 2017, 117, 415-421.	1.8	14
75	Prediction Score for Anticoagulation Control Quality Among Older Adults. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	26
76	Stability of High-Quality Warfarin Anticoagulation in a Community-Based Atrial Fibrillation Cohort: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	19
77	Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF. <i>Europace</i> , 2016, 18, 1135-1142.	0.7	31
78	Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. <i>Circulation</i> , 2016, 134, 1122-1124.	1.6	6
79	A Post-Discharge Smoking-Cessation Intervention for Hospital Patients. <i>American Journal of Preventive Medicine</i> , 2016, 51, 597-608.	1.6	44
80	Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1694-1702.	1.1	21
81	How Well Do Stroke Risk Scores Predict Hemorrhage in Patients With Atrial Fibrillation?. <i>American Journal of Cardiology</i> , 2016, 118, 697-699.	0.7	9
82	Effect of Diabetes and Glycemic Control on Ischemic Stroke Risk in AF Patients. <i>Journal of the American College of Cardiology</i> , 2016, 67, 239-247.	1.2	71
83	Factors influencing left atrial volume in a population with preserved ejection fraction: Left ventricular diastolic dysfunction or clinical factors?. <i>Journal of Cardiology</i> , 2016, 68, 275-281.	0.8	9
84	Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. <i>Heart</i> , 2016, 102, 1036-1043.	1.2	36
85	Comparison of the ATRIA, CHADS ₂ , and CHA ₂ DS ₂ -VASc stroke risk scores in predicting ischaemic stroke in a large Swedish cohort of patients with atrial fibrillation. <i>European Heart Journal</i> , 2016, 37, 3203-3210.	1.0	93
86	Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. <i>Journal of the American Heart Association</i> , 2016, 5, e002197.	1.6	127
87	Novel oral anticoagulants and reversal agents: Considerations for clinical development. <i>American Heart Journal</i> , 2015, 169, 751-757.	1.2	69
88	Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2015, 4, e001349.	1.6	12
89	Atrial Fibrillation Burden and Short-Term Risk of Stroke. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 1040-1047.	2.1	168
90	Comparative effectiveness of post-discharge strategies for hospitalized smokers: study protocol for the Helping HAND 2 randomized controlled trial. <i>BMC Public Health</i> , 2015, 15, 109.	1.2	18

#	ARTICLE	IF	CITATIONS
91	Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). <i>Lancet, The.</i> 2015, 385, 2363-2370.	6.3	123
92	Patients'™ time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. <i>American Heart Journal</i> , 2015, 170, 141-148.e1.	1.2	211
93	Disparities in Cancer Incidence, Stage, and Mortality at Boston Health Care for the Homeless Program. <i>American Journal of Preventive Medicine</i> , 2015, 49, 694-702.	1.6	56
94	Comparison of Frequency and Outcome of Major Gastrointestinal Hemorrhage in Patients With Atrial Fibrillation on Versus Not Receiving Warfarin Therapy (from the ATRIA and ATRIA-CVRN Cohorts). <i>American Journal of Cardiology</i> , 2015, 115, 40-46.	0.7	15
95	Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. <i>European Heart Journal</i> , 2014, 35, 3377-3385.	1.0	154
96	Sustained Care Intervention and Postdischarge Smoking Cessation Among Hospitalized Adults. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 719.	3.8	114
97	Intracranial Hemorrhage Among Patients With Atrial Fibrillation Anticoagulated With Warfarin or Rivaroxaban. <i>Stroke</i> , 2014, 45, 1304-1312.	1.0	187
98	Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). <i>American Heart Journal</i> , 2014, 168, 487-494.	1.2	107
99	Effect of Selective Serotonin Reuptake Inhibitors on Bleeding Risk in Patients With Atrial Fibrillation Taking Warfarin. <i>American Journal of Cardiology</i> , 2014, 114, 583-586.	0.7	68
100	Estimates of Current and Future Incidence and Prevalence of Atrial Fibrillation in the U.S. Adult Population. <i>American Journal of Cardiology</i> , 2013, 112, 1142-1147.	0.7	1,032
101	Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 61, 651-658.	1.2	181
102	A New Risk Scheme to Predict Ischemic Stroke and Other Thromboembolism in Atrial Fibrillation: The ATRIA Study Stroke Risk Score. <i>Journal of the American Heart Association</i> , 2013, 2, e000250.	1.6	315
103	Targeted Minimum Loss-Based Estimation of Causal Effects in Right-Censored Survival Data with Time-Dependent Covariates: Warfarin, Stroke, and Death in Atrial Fibrillation. <i>Journal of Causal Inference</i> , 2013, 1, 235-254.	0.5	7
104	Thirty-Day Mortality After Ischemic Stroke and Intracranial Hemorrhage in Patients With Atrial Fibrillation On and Off Anticoagulants. <i>Stroke</i> , 2012, 43, 1795-1799.	1.0	78
105	Antithrombotic Therapy for Atrial Fibrillation. <i>Chest</i> , 2012, 141, e531S-e575S.	0.4	891
106	Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 883-891.	13.9	8,006
107	Moving the Tipping Point. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 14-21.	0.9	234
108	Response to Letter by Willey. <i>Stroke</i> , 2010, 41, .	1.0	0

#	ARTICLE	IF	CITATIONS
109	Response to Letter Regarding Article, "Impact of Proteinuria and Glomerular Filtration Rate on Risk of Thromboembolism in Atrial Fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study". <i>Circulation</i> , 2009, 120, .	1.6	0
110	The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2009, 2, 474-480.	2.1	747
111	Should Patient Characteristics Influence Target Anticoagulation Intensity for Stroke Prevention in Nonvalvular Atrial Fibrillation?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 297-304.	0.9	96
112	The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation. <i>Annals of Internal Medicine</i> , 2009, 151, 297.	2.0	585
113	Antithrombotic Therapy in Atrial Fibrillation. <i>Chest</i> , 2008, 133, 546S-592S.	0.4	706
114	Warfarin or Not Warfarin?. <i>Annals of Internal Medicine</i> , 2005, 142, 676.	2.0	1
115	A Controlled Trial of Population Management: Diabetes Mellitus: Putting Evidence into Practice (DM-PEP). <i>Diabetes Care</i> , 2004, 27, 2299-2305.	4.3	62
116	The Effect of Warfarin and Intensity of Anticoagulation on Outcome of Intracerebral Hemorrhage. <i>Archives of Internal Medicine</i> , 2004, 164, 880.	4.3	544
117	Antithrombotic Therapy in Atrial Fibrillation. <i>Chest</i> , 2004, 126, 429S-456S.	0.4	519
118	Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2003, 349, 1019-1026.	13.9	1,136
119	A 60-Year-Old Woman With Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2003, 290, 2182.	3.8	6
120	Prevalence of Diagnosed Atrial Fibrillation in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2001, 285, 2370.	3.8	5,547
121	Clinical presentation, processes and outcomes of care for patients with pneumococcal pneumonia. <i>Journal of General Internal Medicine</i> , 2000, 15, 638-646.	1.3	67
122	Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation. <i>Annals of Internal Medicine</i> , 2000, 132, 841.	2.0	5
123	The relation between expectations and outcomes in surgery for sciatica. <i>Journal of General Internal Medicine</i> , 1999, 14, 740-744.	1.3	127
124	Application of outcomes research in occupational low back pain: The Maine Lumbar Spine Study. , 1996, 29, 584-589.		24
125	Elsewhere correspondence. <i>Hepatology</i> , 1987, 7, 1391-1391.	3.6	0